YTHDC2

Across TCGA pan-cancer cohorts, YTHDC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated YTHDC2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher YTHDC2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated YTHDC2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where YTHDC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.747	0.434	.001	53	view →
HNSC	DFS	Tertile	All	0.794	0.539	.010	18	view →
CCRCC	DFS	Tertile	IV	0.099	0.908	.024	13	view →
UCEC	OS	Median	II,III,IV	1.000	0.638	.014	10	view →
LSCC	OS	Tertile	All	0.685	0.903	.010	10	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

YTHDC2–LUAD (DFS)

Open the LUAD breakdown →